
Join to view full profile
60 Temple StSuite 8BNew Haven, CT 06510
Phone+1 203-401-4300
Fax+1 203-401-4301
Dr. Russell is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Russell is Senior Medical Director and has been an investigator for a hundred clinical trials, mostly in CNS but including many organ systems and diseases. He is a neurologist based in New Haven, CT, specializing in movement disorders and neurodegenerative conditions. He completed his medical education at Weill Cornell Medicine, followed by an internship and residency in neurology at Yale-New Haven Medical Center. Dr. Russell has extensive experience in is neurodegenerative diseases, especially movement disorders, dementia, Alzheimer's disease, and Parkinson's disease. He has authored many publications with notable citations and presentations at international conferences. He has extensive expertise in clinical trial design, recruitment, feasibility, regulatory compliance, medical and oversight. His involvement in clinical trials highlights his ongoing contribution to advancing the understanding and treatment of serious diseases, especially neurodegenerative diseases.
Education & Training
Yale-New Haven Medical CenterResidency, Neurology, 1992 - 1995
Yale-New Haven Medical CenterInternship, Internal Medicine, 1991 - 1992
Weill Cornell MedicineClass of 1991
Certifications & Licensure
CT State Medical License 1995 - 2027
PA State Medical License 1995 - 1996
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsQuantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study.Ryan Terry-Lorenzo, Daniel Albrecht, Sabrinia Crouch, Richard Wong, Gordon Loewen
Neuropsychopharmacology. 2025-06-01 - Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study.Ryan Terry-Lorenzo, Daniel Albrecht, Sabrinia Crouch, Richard Wong, Gordon Loewen
Neuropsychopharmacology. 2025-03-01 - 15 citationsEvidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study.Kenneth Marek, David S Russell, Luis Concha-Marambio, Seung Ho Choi, Danna Jennings
Ebiomedicine. 2025-02-01
Press Mentions
Patients May Wait Years for New DrugsApril 30th, 2023
20 Years of Human Embryonic Stem CellsApril 20th, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: